News

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.
The Advertising Standards Authority said the rulings made it ‘crystal clear’ that prescription-only medicines could not be ...
CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...
The drug coverage provision does not mention any specific drug by name, but it could include the GLP-1 agonists, such as ...
Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.
The move follows a dramatic breakup in June between Hims & Hers and Danish drug maker Novo Nordisk, which makes the brand name weight loss drug Wegovy. Novo Nordisk accused the Hims & Hers of ...
The telehealth company stated that its entry to Canada will come as generic Semaglutide hits the market for the first time.
A recent survey highlighted a widespread lack of understanding about the much-publicised GLP-1 weight-loss medications ...
Novo Nordisk seeks EMA approval for 7.2 mg Wegovy dose after trials show 21% weight loss in people with obesity and type 2 diabetes.
Wegovy (semaglutide) is an FDA-approved medication for chronic weight management. Learn more about Wegovy, including how it works and potential risks.
Wegovy, a weight loss drug which reduces cardiovascular risks in obese individuals, launched in India on June 24. Experts ...
Novo Nordisk submits a higher 7.2 mg dose of Wegovy for EMA approval, backed by trials showing 21% weight loss in obesity and ...